Karyopharm Therapeutics Inc. (NASDAQ:KPTI) saw some unusual options trading activity on Monday. Stock traders purchased 827 call options on the stock. This is an increase of 934% compared to the typical volume of 80 call options.

Karyopharm Therapeutics (NASDAQ:KPTI) opened at $9.66 on Thursday. Karyopharm Therapeutics has a 52 week low of $7.48 and a 52 week high of $14.63.

Karyopharm Therapeutics (NASDAQ:KPTI) last posted its quarterly earnings data on Thursday, November 2nd. The company reported ($0.65) EPS for the quarter, missing the consensus estimate of ($0.64) by ($0.01). Karyopharm Therapeutics had a negative return on equity of 76.83% and a negative net margin of 67,267.47%. research analysts predict that Karyopharm Therapeutics will post -2.58 earnings per share for the current year.

In other Karyopharm Therapeutics news, SVP Christopher Brett Primiano sold 27,042 shares of the business’s stock in a transaction dated Tuesday, December 12th. The shares were sold at an average price of $10.28, for a total value of $277,991.76. Following the completion of the sale, the senior vice president now directly owns 11,381 shares of the company’s stock, valued at approximately $116,996.68. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, Director Mansoor Raza Mirza sold 2,882 shares of the business’s stock in a transaction dated Friday, September 15th. The shares were sold at an average price of $11.00, for a total transaction of $31,702.00. Following the completion of the sale, the director now directly owns 2,882 shares of the company’s stock, valued at $31,702. The disclosure for this sale can be found here. Over the last three months, insiders sold 50,382 shares of company stock valued at $533,371. 14.71% of the stock is owned by corporate insiders.

Several hedge funds and other institutional investors have recently bought and sold shares of KPTI. Vanguard Group Inc. raised its stake in shares of Karyopharm Therapeutics by 31.1% during the 2nd quarter. Vanguard Group Inc. now owns 1,621,420 shares of the company’s stock worth $14,675,000 after acquiring an additional 384,658 shares in the last quarter. JPMorgan Chase & Co. raised its stake in shares of Karyopharm Therapeutics by 753.5% during the 3rd quarter. JPMorgan Chase & Co. now owns 307,200 shares of the company’s stock worth $3,342,000 after acquiring an additional 271,208 shares in the last quarter. Tekla Capital Management LLC raised its stake in shares of Karyopharm Therapeutics by 25.0% during the 2nd quarter. Tekla Capital Management LLC now owns 756,679 shares of the company’s stock worth $6,848,000 after acquiring an additional 151,455 shares in the last quarter. Northern Trust Corp raised its stake in shares of Karyopharm Therapeutics by 36.5% during the 2nd quarter. Northern Trust Corp now owns 405,374 shares of the company’s stock worth $3,668,000 after acquiring an additional 108,369 shares in the last quarter. Finally, Iguana Healthcare Management LLC raised its stake in shares of Karyopharm Therapeutics by 33.3% during the 3rd quarter. Iguana Healthcare Management LLC now owns 400,000 shares of the company’s stock worth $4,392,000 after acquiring an additional 100,000 shares in the last quarter. Hedge funds and other institutional investors own 60.92% of the company’s stock.

Several equities research analysts have recently weighed in on the stock. HC Wainwright reaffirmed a “buy” rating and issued a $23.00 price target on shares of Karyopharm Therapeutics in a research report on Wednesday, November 15th. assumed coverage on shares of Karyopharm Therapeutics in a research report on Wednesday, November 15th. They issued a “buy” rating and a $23.00 price target for the company. ValuEngine cut shares of Karyopharm Therapeutics from a “hold” rating to a “sell” rating in a research report on Thursday, August 31st. Royal Bank of Canada reaffirmed a “buy” rating and issued a $15.00 price target on shares of Karyopharm Therapeutics in a research report on Friday, November 3rd. Finally, Robert W. Baird reaffirmed a “buy” rating on shares of Karyopharm Therapeutics in a research report on Friday, November 3rd. Two research analysts have rated the stock with a sell rating, one has assigned a hold rating and eight have given a buy rating to the stock. Karyopharm Therapeutics presently has an average rating of “Buy” and a consensus target price of $17.33.

TRADEMARK VIOLATION WARNING: “Traders Buy High Volume of Call Options on Karyopharm Therapeutics (KPTI)” was first posted by Watch List News and is the property of of Watch List News. If you are reading this article on another website, it was stolen and reposted in violation of U.S. and international copyright & trademark legislation. The legal version of this article can be accessed at https://www.watchlistnews.com/traders-buy-high-volume-of-call-options-on-karyopharm-therapeutics-kpti/1762780.html.

Karyopharm Therapeutics Company Profile

Karyopharm Therapeutics Inc is a clinical-stage pharmaceutical company. The Company is focused on the discovery, development and commercialization of drugs directed against nuclear transport and related targets for the treatment of cancer and other diseases. It has discovered and is developing small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein, XPO1.

Receive News & Ratings for Karyopharm Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Karyopharm Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.